Chimerix, a Durham-based biopharmaceutical company that’s developing medicines to treat cancer and other diseases, has received good regulatory news for its potential antiviral treatment for smallpox.
Read More
Thursday was not a good day for North Carolina life science companies. While BioDelivery Sciences reported a big profit, BioCryst, Aerie, TransEnterix, Chimerix and vTv Therapeutics all reported signifcant losses.
Read More
Two Durham-based life science firms – Precision BioSciences and Chimerix – reported losses this week. Here’s the latest.
Read More
Chimerix has named Allen Melemed, an MD and a former Elil Lilly executive, as its chief medical officer.
Read More
The Durham-based biopharmaceutical company, which develops antiviral medicines for unmet medical needs, this week announced it had received clearance from the FDA for a rolling submission of its New Drug Application for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.
Read More
DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties. Chimerix said it has the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.
Read More
Three publicly traded Triangle-based biotech and pharmaceutical firms are all reporting losses for their most recent quarter. Here are the details:
Read More
Chimerix has struck a licensing and development deal for its experimental antiviral drug brincidofovir with SymBio Pharmaceuticals in a deal that could be worth as much as $180 million plus royalties.
Read More
This week, the Durham-based biopharmaceutical company announced an agreement with Cantex Pharmaceuticals for the worldwide license of CX-01.
Read More
